We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A picture of Laura Elizabeth Lansdowne

Laura Elizabeth Lansdowne profile page

Managing Editor

 at Technology Networks


As managing editor, Laura works with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She oversees the in-house editorial team and works directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.


Education


University of Kent  

Nottingham Trent University  


Areas of Expertise



Got a Question for Laura Elizabeth Lansdowne?


Get in touch using the contact form linked here and we’ll get back to you shortly



Published Content
Total: 409
MicroTissue: Transforming Drug Discovery content piece image
Industry Insight

MicroTissue: Transforming Drug Discovery

We spoke to Ping Yeh, CEO of StemoniX, to learn more about the company and their mission. With an aim to accelerate and optimize drug discovery and development, StemoniX creates ‘ready-to-use’ microtissue plates that mimic the native organ tissue.
Testosterone: Why the Incidence of Multiple Sclerosis is Lower in Men  content piece image
News

Testosterone: Why the Incidence of Multiple Sclerosis is Lower in Men

Researchers have discovered why men are much less likely to develop multiple sclerosis (MS) — high levels of testosterone. Testosterone triggers production of the cytokine IL-33 protecting them from the disease.
Microfluidic Method Identifies Rare Antibodies with Therapeutic Potential content piece image
Article

Microfluidic Method Identifies Rare Antibodies with Therapeutic Potential

A novel microfluidic platform, able to rapidly isolate and identify rare antibodies from a vast repertoire of human B cells, has been developed by scientists. This technology could possess the ability to support and enhance the development of novel vaccines and biopharmaceuticals in the future.
Article

Promoting the Use of AI within the Life Sciences Industry

Awareness of Artificial Intelligence (AI), Machine Learning (ML) and Neuro-linguistic Programming (NLP) is ever-increasing, with AI being one of the most talked about technologies across multiple industries. The Pistoia Alliance recently surveyed 374 life science professionals to determine the impact of AI, ML and NLP on the life sciences industry.
News

Researchers Identify Druggable Genomic Targets in Malaria Parasite

Using whole-genome analysis and chemogenomics, scientists have discovered novel antimalarial drug targets and drug-resistance genes. The researchers analyzed >250 Plasmodium falciparum cell lines, which were resistant to 37 different anti-malarial compounds.
News

Ibuprofen Use Could Be Linked to Male Reproductive Disorders

New research indicates that analgesic compounds, such as ibuprofen, may be associated with male reproductive problems. Researchers recently conducted a study to investigate the effects of ibuprofen on the pituitary–testis axis in young males.
News

£70M Meant for Cancer Drug Development is Reassigned to Prepare for Brexit

At the end of last year, the Health Committee held a meeting to discuss Brexit, more specifically the impact this will have on the discovery, development and regulation of medicines, medical devices and biopharmaceuticals.
G Protein-coupled Receptors in Drug Discovery content piece image
Infographic

G Protein-coupled Receptors in Drug Discovery

G protein-coupled receptors (GPCRs) are the largest human membrane protein family. This infographic summarizes approved and investigational drugs, GPCR targets, and associated indications.
News

Melanoma Cell Growth Inhibited by Novel Compound

Researchers have developed a novel compound with the ability to inhibit melanoma cell growth. This research, published today, could pave the way for the development of a new class of cancer therapies, with improved safety and efficacy.
4 Things to Consider When Adopting Lab Automation content piece image
Listicle

4 Things to Consider When Adopting Lab Automation

This list aims to address some of the key challenges and ‘steps to success’ when implementing lab automation.
Advertisement